natgillin/translations-raw huggingface dataset:
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE
Lyophilisate (10x1 dose) + solvent (10x1 ml) Lyophilisate (50x1 dose) + solvent (50x1 ml)
Liofilizat (10 x 1 odmerek) in vehikel (10 x 1 ml) Liofilizat (50 x 1 odmerek) in vehikel (50 x1 ml)
No effects other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), če je potrebno Drugi učinki, razen tistih, ki so navedeni v poglavju 4.6 »Neželeni učinki«, niso znani, razen povišane temperature , ki izjemoma lahko traja pet dni.
Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule:
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte odmerek (1 ml) cepiva v podkožje, po naslednjem razporedu:
The duration of immunity after the last re-vaccination is 3 years for rhinotracheitis, calicivirosis and panleucopenia components.
Trajanje imunosti po zadnjem ponovnem cepljenju je 3 leta za komponente kužnega rinotraheitisa, kalicivirozein mačje panleukopenije.
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, and feline panleucopenia virus.
Vzpodbuja aktivno imunost proti virusu kužnega rinotraheitisa, kalicivirusu in virusu panleukopenije mačk.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Pack of 10 bottles of lyophilisate and 10 bottles of solvent Pack of 50 bottles of lyophilisate and 50 bottles of solvent
Vsebnik z 10 stekleničkami liofilizata in 10 stekleničkami vehikla Vsebnik s 50 stekleničkami liofilizata in 50 stekleničkami vehikla
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate bottle
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Purevax RCP lyophilisate and solvent for suspension for injection
Purevax RCP liofilizat in vehikel suspenzijo za injiciranje
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Inaktivirani antigeni kalici virusa mačk (seva FCV 431 in G1) ....................... ≥ 2,0 enot v testu ELISA Atenuiran virus panleukopenije mačk (PLI IV) .............................................................. ≥ 103,5 CCID501
Vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia.
Cepivo proti virusnemu rinotraheitisu, kalicivirusu in panleukopeniji mačk.
Purevax RCP lyophilisate and solvent for suspension for injection.
Purevax RCP Liofilizat in vehikel za suspenzijo za injiciranje
No effect other than those already mentioned in section on “Adverse reactions” have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days.
Po večkratnem dajanju drugi učinki, razen tistih ki so navedeni v poglavju »Neželeni učinki«, niso znani.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens .......................... ≥ 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1) ......................... ≥ 2,0 enot v testu ELISA
Onsets of immunity have been demonstrated 1 week after primary vaccination course for the rhinotracheitis, calicivirus and panleucopenia components.
Imunost proti kužnemu rinotraheitisu, kalicivirusu mačk in mačji panleukopeniji nastopi 1 teden po osnovnem cepljenju.
ANNEX II A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
This means that it is similar to a ‘reference medicine' containing the same active substance, but is given in a different way.
To pomeni, da je podobno referenčnemu zdravilu, ki vsebuje enako zdravilno učinkovino, vendar se daje drugače.
Nyxoid can be used in adults and adolescents from 14 years of age.
Zdravilo Nyxoid se lahko uporablja pri odraslih in mladostnikih, starejših od 14 let.
The full EPAR for Nyxoid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nyxoid je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Nyxoid?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Nyxoid?
This is a summary of the European public assessment report (EPAR) for Nyxoid.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Nyxoid.
Therefore, the European Medicines Agency decided that Nyxoid's benefits are greater than its risks and recommended that it be approved for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Nyxoid večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
Nyxoid is a ‘hybrid medicine'.
Zdravilo Nyxoid je „hibridno zdravilo“.
The company that markets Nyxoid will issue educational materials, including a video, for healthcare professionals and for patients with detailed information on how to use the medicine.
Družba, ki trži zdravilo Nyxoid, bo izdala izobraževalno gradivo, vključno z videoposnetkom, za zdravstvene delavce in bolnike s podrobnimi informacijami o načinu uporabe zdravila.
Other information about Nyxoid
Druge informacije o zdravilu Nyxoid
In addition, a study involving 38 healthy volunteers showed that, when given by a healthcare professional, Nyxoid 2 mg given as a spray into the nose produced a similar level of naloxone in the body as naloxone given in the usual dose of 0.4 mg by injection into a muscle.
Poleg tega so s študijo, ki je vključevala 38 zdravih prostovoljcev, dokazali, da 2-miligramski odmerek zdravila Nyxoid , ki se daje v obliki pršila v nos, proizvede podobno raven naloksona v telesu kot nalokson, ki se daje v običajnem odmerku 0,4 mg z injiciranjem v mišico.
The company will also conduct a study on the effectiveness of Nyxoid when given by people with no medical training.
Opravila bo tudi študijo o učinkovitosti zdravila Nyxoid, kadar ga dajejo osebe brez medicinskega usposabljanja.
Naloxone rapidly blocks these receptors, ending the opioid's effects such as slow breathing.
Nalokson hitro zavre te receptorje in prekine učinke opioida, kot je počasno dihanje.
The most common side effect with Nyxoid (which may affect more than 1 in 10 people) is nausea (feeling sick).
Najpogostejši neželeni učinek zdravila Nyxoid (ki se lahko pojavi pri več kot 1 osebi od 10) je navzeja (siljenje na bruhanje).
There is also no risk of needle injury with Nyxoid, and this could encourage members of the public to provide treatment promptly.
Pri zdravilu Nyxoid prav tako ni tveganja za poškodbe z iglo, kar bi lahko spodbudilo splošno javnost, da takoj izvede zdravljenje.
Nyxoid is a nasal spray available in single-dose containers (1.8 mg).
Zdravilo Nyxoid je nosno pršilo, ki je na voljo v enoodmernih vsebnikih (1,8 mg).
Opioids work by attaching to and activating opioid receptors (targets) in the body.
Opioidi delujejo tako, da se vežejo na opioidne receptorje (prijemališča) v telesu in jih aktivirajo.
If the first dose works well but the patient later worsens a second dose should be given immediately in the other nostril.
Če prvi odmerek učinkuje, vendar se bolnikovo stanje pozneje poslabša, je treba v drugo nosnico takoj dati drugi odmerek.
It is not intended to provide practical advice on how to use Nyxoid.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nyxoid have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Nyxoid upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is Nyxoid approved?
Zakaj je bilo zdravilo Nyxoid odobreno?
What are the risks associated with Nyxoid?
Kakšna tveganja so povezana z zdravilom Nyxoid?
Naloxone, the active substance in Nyxoid, has been widely used in emergency medicine since the 1970s to treat opioid overdose.
Nalokson, zdravilna učinkovina v zdravilu Nyxoid, se že od 70. let 20. stoletja pogosto uporablja v urgentni medicine za zdravljenje prevelikega odmerjanja opioidov.
The safety and effectiveness of naloxone as an antidote for opioid overdose are well known.
Varnost in učinkovitost naloksona kot protistrupa za prevelik odmerek opioida sta dobro znani.
Signs of overdose include pinpoint pupils, abnormally slow and irregular breathing, severe sleepiness and unresponsiveness to touch or loud noises.
Znaki prevelikega odmerjanja vključujejo izrazito zožene zenice, nenormalno počasno in neredno dihanje, hudo zaspanost in neodzivnost na dotik ali glasen hrup.
Compared with emergency treatments for opioid overdose given by injection, Nyxoid can be given by people with no medical training because it is sprayed into the nose.
V primerjavi z nujnimi zdravili pri prevelikem odmerjanju opioidov, ki se dajejo z injiciranjem, lahko zdravilo Nyxoid dajejo osebe brez medicinskega usposabljanja, saj se razprši v nos.
What is Nyxoid and what is it used for?
Kaj je zdravilo Nyxoid in za kaj se uporablja?
The company provided data from the published literature showing that naloxone is effective in treating opioid overdose when given by injection (the standard treatment for opioid overdose) as well as into the nose.
Družba je predložila podatke iz objavljene literature, ki kažejo, da je nalokson učinkovit pri zdravljenju prevelikega odmerjanja opioidov, kadar se daje z injekcijo (standardno zdravljenje prevelikega odmerjanja opioidov) ali v nos.
While the reference medicine Naloxon HCl B. Braun is given by injection, Nyxoid is given as a spray into the nose.
Referenčno zdravilo Naloxon HCl B. Braun se daje z injiciranjem, zdravilo Nyxoid pa kot pršilo v nos.
For more information about treatment with Nyxoid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Nyxoid preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What benefits of Nyxoid have been shown in studies?
Kakšne koristi je zdravilo Nyxoid izkazalo v študijah?
Nyxoid is a medicine used for emergency treatment in case of known or suspected overdose of opioid drugs (such as heroin or morphine).
Zdravilo Nyxoid se uporablja za nujno zdravljenje v primeru prevelikega odmerka opioidov (kot sta heroin ali morfin) ali sumu nanj.
For practical information about using Nyxoid, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Nyxoid naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Nyxoid, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Nyxoid glejte navodilo za uporabo.
How does Nyxoid work?
Kako zdravilo Nyxoid deluje?
How is Nyxoid used?
Kako se zdravilo Nyxoid uporablja?
The active substance in Nyxoid, naloxone, counteracts the effects of opioid drugs.
Zdravilna učinkovina v zdravilu Nyxoid, nalokson, izniči delovanje opioidov.
It contains the active substance naloxone.
Vsebuje zdravilno učinkovino nalokson.
The recommended dose is one spray into one nostril given immediately on suspecting an opioid overdose and while awaiting emergency services; if the first dose does not have an effect, a second dose should be given after 2-3 minutes in the other nostril.
Priporočeni odmerek je en vpih v eno nosnico, ki se da takoj po sumu na prevelik odmerek opioida in med čakanjem na prihod reševalcev.
Typical opioid withdrawal syndrome is expected after Nyxoid is given to people addicted to opioids; symptoms include restlessness, agitation, feeling or being sick, a fast heart rate and sweating.
Simptomi vključujejo nemir, vznemirjenost, siljenje na bruhanje ali bruhanje, hiter srčni utrip in znojenje.
The European Commission granted a marketing authorisation valid throughout the European Union for Moventig on 8 December 2014.
Evropska komisija je dovoljenje za promet z zdravilom Moventig, veljavno po vsej Evropski uniji, izdala 8. decembra 2014.
In terms of safety, the side effects were considered acceptable or manageable.
Kar zadeva varnost so se neželeni učinki šteli za sprejemljive ali obvladljive.
What measures are being taken to ensure the safe and effective use of Moventig?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Moventig?
The recommended dose is one 25 mg tablet a day.
Priporočen odmerek je ena 25-miligramska tableta na dan.
The full EPAR and risk management plan summary for Moventig can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Moventig sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What is Moventig and what is it used for?
Kaj je zdravilo Moventig in za kaj se uporablja?
The response to treatment was based on an improvement of the number of spontaneous bowel movements per week which had to be maintained for most of the duration of the study.
Odziv na zdravljenje je temeljil na povečanju števila spontanih iztrebljanj na teden, ki ga je bilo treba ohranjati večji del obdobja študije.
Other information about Moventig
Druge informacije o zdravilu Moventig
Although studies in patients with cancerrelated pain had not been conducted, based on the mechanism of action of the medicine, the benefit for these patients was not expected to be different but the safety should be closely monitored.
Čeprav na bolnikih z bolečinami zaradi raka niso bile izvedene študije, ki bi temeljile na mehanizmu učinkovanja zdravila, korist za te bolnike naj ne bi bila drugačna, vendar bi bilo treba skrbno spremljati varnost.
It is not intended to provide practical advice on how to use Moventig.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
A risk management plan has been developed to ensure that Moventig is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Moventig je bil pripravljen načrt obvladovanja tveganj.
This is a summary of the European public assessment report (EPAR) for Moventig.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Moventig.
What benefits of Moventig have been shown in studies?
Kakšne koristi je zdravilo Moventig izkazalo v študijah?
What are the risks associated with Moventig?
Kakšna tveganja so povezana z zdravilom Moventig?
Why is Moventig approved?
Zakaj je bilo zdravilo Moventig odobreno?
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Moventig's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Moventig večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
It must also not be used with certain medicines that affect the way Moventig is broken down in the body.
Prav tako se ne sme uporabljati skupaj z nekaterimi zdravili, ki vplivajo na njegovo razgradnjo v telesu.
Moventig is available as tablets (12.5 and 25 mg).
Zdravilo Moventig je na voljo v tabletah (12,5 mg in 25 mg).
A lower starting dose of 12.5 mg may be prescribed in patients with moderately or severely reduced kidney function or who are taking certain other medicines that increase the effects of Moventig.
Manjši začetni odmerek 12,5 mg se lahko predpiše bolnikom z zmerno ali hudo odpovedjo ledvic ali bolnikom, ki jemljejo nekatera druga zdravila, ki povečujejo učinke zdravila Moventig.
The most common side effects with Moventig (which may affect more than 5 in 100 people) are abdominal pain (stomach ache), diarrhoea, nausea (feeling sick), headache and flatulence (passing wind).
Najpogostejši neželeni učinki zdravila Moventig (ki lahko prizadenejo več kot 5 od 100 oseb) so abdominalne bolečine (bolečine v trebuhu), driska, navzea (slabost), glavobol in flatulenca (vetrovi).
This means that it attaches to a specific type of opioid receptor called the ‘mu-opioid receptor' and blocks opioids from binding to these receptors.
To pomeni, da se veže na določeno vrsto opioidnega receptorja, ki se imenuje „muopioidni receptor“, in blokira vezavo opioidov na te receptorje.
It is used in patients in whom treatment with laxatives has failed.
Uporablja se pri bolnikih, pri katerih je bilo zdravljenje z odvajali neuspešno.
For more information about treatment with Moventig, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Moventig preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions reported with Moventig, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev, o katerih so poročali pri uporabi zdravila Moventig, glejte navodilo za uporabo.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Moventig, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Moventig in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
When looking at the results of both main studies together, 48% (115 out of 241) of adults who previously had an inadequate response to laxatives and who took 25 mg Moventig responded to treatment compared with 30% (72 out of 239) of adults on placebo.
Iz skupnih rezultatov obeh glavnih študij je razvidno, da se je na zdravljenje odzvalo 48 % (115 od 241) odraslih, ki so se prej nezadostno odzvali na odvajala in so prejemali 25 mg zdravila Moventig, v primerjavi s 30 % (72 od 239) odraslih, ki so prejemali placebo.
The studies involved 1,352 adults with constipation caused by opioids that were being used to treat non-cancer pain, half of whom had an inadequate response to laxatives (720).
V študijo je bilo vključenih 1 352 odraslih z zaprtjem, povzročenim z opioidi, ki so se uporabljali za zdravljenje bolečin, ki niso bile povezane z rakom, od katerih se je polovica neustrezno odzvala na odvajala (720).
However, these receptors are also found in the gut and when opioids attach to the gut receptors, they reduce the movement of the gut and can cause constipation.
Vendar so ti receptorji tudi v črevesju, in če se opioidi vežejo na receptorje v črevesju, zmanjšajo gibanje črevesja in lahko povzročijo zaprtje.
Naloxegol is less able to enter the brain than naloxone, meaning that it can block the mu-opioid receptors in the gut but less in the brain.
Naloksegol ima manjšo sposobnost prehajanja v možgane kot nalokson, kar pomeni, da lahko blokira mu-opioidne receptorje v črevesju, manj pa v možganih.
Moventig must not be used in patients who have or who are at high risk of bowel obstruction (blockage in the gut) or in patients with cancer who are at a high risk of gastro-intestinal perforation (a hole that develops in the wall of the gut).
Zdravilo Moventig se ne sme uporabljati pri bolnikih, ki imajo ali bi zelo verjetno lahko imeli obstrukcijo (zaporo) črevesja, ali pri bolnikih z rakom, ki so izpostavljeni velikemu tveganju za perforacijo prebavil (predrtje stene črevesja).
Moventig is a medicine used in adults to treat constipation caused by pain relief medicines called opioids.
Moventig je zdravilo, ki se uporablja pri odraslih za zdravljenje zaprtja, povzročenega z zdravili za lajšanje bolečin, imenovanimi opioidi.
For practical information about using Moventig, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Moventig naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The majority of side effects affecting the gut were mild to moderate, occurred early in treatment and got better during continued treatment.
Večina neželenih učinkov na prebavilih je bila razvrščenih med blage do zmerne, pojavili so se zgodaj med zdravljenjem in so med nadaljevanjem zdravljenja izzveneli.
The CHMP considered that Moventig had shown a clinically relevant benefit when used in adults who have not responded adequately to previous treatment with laxatives.
Po mnenju odbora CHMP je zdravilo Moventig pokazalo pomembno klinično korist pri uporabi pri odraslih, ki se niso zadostno odzvali na predhodno zdravljenje z odvajali.
For adults who took 12.5 mg Moventig and who previously had an inadequate response to laxatives, 43% (102 out of 240) responded to treatment.
Pri odraslih, ki so prejemali 12,5 mg zdravila Moventig in so se prej nezadostno odzvali na odvajala, se jih je na zdravljenje odzvalo 43 % (102 od 240).
Before starting treatment with Moventig, treatment with laxatives should be stopped.
Pred začetkom zdravljenja z zdravilom Moventig je priporočljivo prekiniti zdravljenje z odvajali.
How is Moventig used?
Kako se zdravilo Moventig uporablja?
People either received Moventig (at 12.5 and 25 mg) or placebo (a dummy treatment) for 12 weeks.
Bolniki so 12 tednov prejemali Moventig (po 12,5 mg ali 25 mg) ali placebo (zdravilo brez zdravilne učinkovine).
By blocking receptors in the gut, Moventig reduces the constipation due to opioids, but does not interfere with their pain relief effects.
Zdravilo Moventig z blokiranjem receptorjev v črevesju zmanjšuje zaprtje zaradi opioidov, vendar ne učinkuje negativno na lajšanje bolečin.
The active substance in Moventig, naloxegol, is a peripheral mu-opioid-receptor antagonist.
Zdravilo Moventig vsebuje zdravilno učinkovino naloksegol, ki je periferni antagonist mu-opioidnih receptorjev.
Opioids relieve pain by attaching to ‘opioid receptors' in the brain and spinal cord.
Opioidi lajšajo bolečino z vezavo na opioidne receptorje v možganih in hrbtenjači.
Moventig contains the active substance naloxegol.
Moventig vsebuje zdravilno učinkovino naloksegol.
Naloxegol is derived from naloxone, a well-known substance that is used to block the action of opioids.
Naloksegol je derivat naloksona, znane učinkovine, ki se uporablja za zaviranje učinkovanja opioidov.
How does Moventig work?
Kako zdravilo Moventig deluje?
Moventig has been shown to be effective at treating constipation in adults who had an inadequate response to laxatives in two main studies.
Zdravilo Moventing se je v dveh glavnih študijah izkazalo za učinkovito pri zdravljenju zaprtja pri odraslih z nezadostnim odzivom na odvajala.
Take 3 times per day; morning, afternoon and evening.
Vzemite 3-krat na dan: zjutraj, popoldne in zvečer.
† and ‡
† in ‡
Ribavirin can be very damaging to an unborn baby.
Ribavirin je lahko zelo škodljiv za nerojenega otroka.
Date of first authorisation: 18 July 2011 Date of latest renewal: 18 February 2016
Datum zadnjega podaljšanja: 18. februar 2016